With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving
The COVID-19 pandemic has brought healthcare guidelines and scientific advances front-of-mind on a global scale, in the process highlighting long-standing gaps in health literacy as well as
For episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s the company’s director of oncology advocacy and government affairs, to talk
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.